logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Ming Fai Chan

This inventor holds 39 USPTO granted patents, primarily in Therapeutic Compounds. Top assignees: Allergan, Inc., Texas Biotechnology Corporation, Immunopharmaceutics, Inc.. Active years: 1991-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ming Fai Chan. Retrieved from https://idiyas.com/inventor/ming-fai-chan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 39

% Patents Active = 92.3

Average Co-Inventor Count = 2.5

ph-index = 16

Forward Citations = 967(Granted Patents)


Location History:

  • Lake Bluff, IL (US) (1992 - 1993)
  • Gurnee, IL (US) (1994)
  • Santa Ana, CA (US) (1991 - 1995)
  • San Diego, CA (US) (1993 - 2003)
  • Encinitas, CA (US) (1998 - 2009)

Company Filing History:

goldMedal18 out of 2,287 
 
Allergan, Inc.
 patents
silverMedal14 out of 37 
 
Texas Biotechnology Corporation
 patents
bronzeMedal3 out of 3 
 
Immunopharmaceutics, Inc.
 patents
4. 1 out of 228 
 
Allergan Sales, Inc.
 patents
5. 1 out of 8 
 
Celmed Oncology (USA), Inc.
 patents
6. 1 out of 9 
 
Encysive Pharmaceuticals, Inc.
 patents
7. 1 out of 5 
 
Newbiotics, Inc.
 patents

Years Active: 1991-2009

Loading Chart...
Areas of Expertise:
Therapeutic Compounds
Enzyme Catalysis
Sulfonamides
Prostaglandins
Endothelin Modulation
Intraocular Pressure
Homo-Prostaglandin Derivatives
Biphenylsulfonamides
Cyclopentane Derivatives
Ocular Hypotensives
Phosphoramidates
Cyclic Peptides
39 patents (USPTO):Explore Patents
1. 7605144 - Enzyme catalyzed therapeutic compounds (2009-10-20),
2. 6683061 - Enzyme catalyzed therapeutic activation (2004-01-27),
3. 6613804 - Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin (2003-09-02),
4. 6541498 - Benzenesulfonamides and the use thereof to modulate the activity of endothelin (2003-04-01),
5. 6384261 - Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin (2002-05-07),
6. 6376523 - Benzenesulfonamides and the use thereof to modulate the activity of endothelin (2002-04-23),
7. 6342610 - N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin (2002-01-29),
8. 6331637 - N-Alkyl, N-Alkenyl, N-Alkynyl, N-Aryl and N-fused bicyclo or tricyclo thienyl-, furyl-,and Pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin (2001-12-18),
9. 6265428 - Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin (2001-07-24),
10. 6258844 - Cyclopentane (ene) oic acid, 2-alkenyl derivatives as therapeutic agents (2001-07-10),
11. 6030991 - Benzenesulfonamides and the use thereof to modulate the activity of (2000-02-29),
12. 5977117 - Substituted phenyl compounds and derivatives thereof that modulate the (1999-11-02),
13. 5962490 - Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that (1999-10-05),
14. 5958905 - Phosphoramidates, phosphinic amides and related compounds and the use (1999-09-28),
15. 5767154 - 5-trans-prostaglandins of the F series and their use as ocular (1998-06-16),

Title: Ming Fai Chan: Innovating Therapeutics through Patented Technology

Introduction

Ming Fai Chan, a prominent inventor based in San Diego, CA, has made significant contributions to the field of therapeutic compounds. With a remarkable portfolio of 39 patents, Chan’s work focuses on innovations that target complex diseases, prominently cancer. His inventions have the potential to revolutionize treatment modalities and make lasting impacts on patient care.

Latest Patents

Among his latest innovations, Chan has developed two notable patents:

1. **Enzyme Catalyzed Therapeutic Compounds** - This invention introduces novel compounds derived from a 1,5-substituted pyrimidine derivative or its analogs, including substituted furano-pyrimidone analogs. These compounds are designed to effectively treat or prevent diseases, particularly cancer.

2. **Enzyme Catalyzed Therapeutic Activation** - This invention details novel substrate compounds that uniquely inhibit the proliferation of pathological cells. The enzyme involved facilitates the conversion of the substrate into a cellular toxin or releases a toxic byproduct, thus targeting cells that overexpress a specific enzyme, which often confers resistance to traditional therapies. This method also includes the use of prodrugs that can be combined with other chemotherapy or radiation therapies.

Career Highlights

Throughout his career, Ming Fai Chan has associated with leading firms in the biotechnology industry. Notable companies he has worked with include Allergan, Inc. and Texas Biotechnology Corporation. His professional journey reflects his commitment to advancing medical science through innovative research and development.

Collaborations

In his pursuit of innovation, Chan has collaborated with skilled professionals in the field. Noteworthy coworkers include Vitukudi Narayanaiyengar Balaji and Adam Kois, with whom he has shared ideas and developed groundbreaking therapeutic solutions.

Conclusion

Ming Fai Chan stands out as a trailblazer in the area of therapeutic innovations. His 39 patents, particularly in enzyme-catalyzed compounds and activation processes, underscore his role as a vital contributor to the medical and research community. The applications of his inventions hold promise for enhancing treatment options for diseases like cancer, thereby improving patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…